Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The MT “upgrade” that bugged me the most was when they killed the toggle in raw data between trade volume and cumulative daily volume. When I asked him about it he said it would not be coming back bc they changed the was they store volume data on historical ticks.
Seems to me that several months ago I was able to do just that - look at a 10 day/1 minute chart in MT for an option and figure out when and for how much a certain trade went down. Just now I couldn’t raise any more than part of Friday’s data on a chart.
It seems to me that the people on this board who know the least about patent law have the most to say about it.
Using Medved Trader or Ameritrade’s Thinkorswim, if I put an option symbol into a watchlist I can collect time and sales data for it. These platforms don’t allow me to see that data historically unless I have the particular symbol on an active list. But I can open a time and sales window for any option and see trades going forward.
For the particular trades we were discussing I used Thinkorswim’s “see quote detail” feature for each of the options in question and from there opened a one minute chart for the day. Fortunately, locating those large trades was easy.
The prices were $.11 for the $10 put and $.42 for the $12 put, so this is clearly a bear put spread.
Sorry but it looks definitely like a bear put spread. The prices ($.11 and $.42) indicate that the $10 put was sold and the $12 put was bought. That’s either a bearish bet or a partial hedge against a long position. It could also be part of a more complex strategy with legs that we haven’t identified.
The expiration selection is certainly curious - October?
I think your scenarios one and two are somewhat possible, three and four highly unlikely and five out of the question.
I continue to suspect that there is a complex strategy in play for which we can’t see all the parts. This much delta in play is so far out of my league that I am not going to speculate further.
Cost $.31 x 100 per spread.
Max yield $2 x 100 per spread.
Total cost $31 per spread x 14000 spreads = $424 thousand.
Max profit $169 per spread x 14000 spreads = $2.4 million.
Commissions ignored.
Curiously, the total dollar cost ($434k + commission) is similar to the last large put play we saw here. Could possibly be related, and/or this could be a complex trade strategy with other legs that we don’t see or don’t see yet.
The difference is, assuming the buyer is otherwise long, that $400k spent on long calls is a bet/gamble whereas $400k spent on long puts is a hedge.
Rather than saying “research” with quotation marks, I’d rather say “so-called research,” or even better, “faux research,” both without quotation marks.
I just got prescribed a mini dose of a generic beta blocker (for PVCs and PACs - Holter monitor showed over 22,000 in 24 hour period), made by one of our arch enemies, Dr. Reddy’s. Otherwise no CVD or risk factors.
The effective date of that short report is Monday 8-12. 8-15 was just the settlement date for trades effective 8-12. That’s even more curious however, because On 8-12 we bounced off the low of 13,80 and closed at 14.29. If the shorts didn’t cover that day they were looking for more downside, OR much of that added short interest could be hedged. It’s always nearly impossible for retail to see the whole picture.
Right! This is not a bar room where any wild opinion passes as fact. The stuff you threw out came out of your imagination or stuff you thought you recalled from years ago, and for that you should expect a vigorous cross.
Forgetaboutit! No outcomes study means no CVD label. Lowering triglycerides has not been proven to have any benefit on cardiovascular disease. In my opinion you will lose whatever you invest in Acasti.
Btw, don’t get JL started on krill oil.
BB, I think you are absolutely correct. I do not believe that JT has acted improperly at any time and I am certain that he did not have any advance specific knowledge of the FDA’s blitz move late in the game. But I also believe that while he publicly displayed confidence that everything was on track he was right to suspect something could go wrong, That’s his job.
I think he meant a .zip archive rather than a zip drive.
Not at all. In their investment bank role they buy and sell for guaranteed profit, and that's exactly what they did. If they hold long or short positions in their trading role, that's another business segment, and I'm sure they are doing that as well. I wouldn't worry about the banks.
Max pain is totally irrelevant this week because there is no mass behind it; that is, the open interest is insignificant on balance.
Just got out of visit at cardiology clinic (had Holter device attached). While I was in the waiting room the Pfizer rep came in. The room got quiet and we both had to wait a little so I said “I hear you guys are going to be adding Vascepa to your bags.” He did not say “how did you know that?” He did however indicate that he knew something but nothing was public. He told me he’s on Vascepa himself and loves it. He also knew there would be competition in the bidding, from Novartis and others. He said he would be ecstatic to have Vascepa in his bag and he’d be all over it.
I think the term “smalll-to-substantial” is referring to the range of benefits available to the very large population they say are eligible for Vascepa. It sounds to me like they’re saying that everyone will benefit at least a little and many will benefit “substantially,” depending on the health of the individual. In other words, “This is a mega-blockbuster.”
Turby, can you tell us if you paid out-of-pocket for that test group and if so how much you paid. Thank you in advance.
$2.43
If I’m not awake in 2023 my daughter is going to kill me and my grandson is going to hate me. So it’s settled.
Looks to me like 500 Oct $16 puts were sold 7 minutes after the 1000 buy, and another 250 were sold 19 minutes after that. If it was the same party doing all three trades then he has 250 puts left and he scalped profit off the ones he sold, $.02 on the first sale and &.10 on the second.
The extremely heavy volume this morning is suggesting that the line is being defended so far. There are plenty of buyers at this price but also enough sellers to satisfy the demand.
Big Bank: “Hey Amarin, we’ll be happy to let you play on our court but there is an initiation ritual you have to go through. We call it the shareholder gangbang and it’s gonna be a lot of fun.”
Oh yeah, underwriters will probably defend $18 just like they defended $19 after the last raise back in November. Oh, wait a minute they let it go down to $12 and change and the buyers were underwater for three months after that offering closed. I sure hope JT has a plan.
That should be TSOI, not TSIO.
I think you’re wrong there. The listing was implying a similarity between an FDA-approved drug and this supplement, similar to the way approved generic medicines say “compare to [brand name X]” and I don’t think they are allowed to imply any such comparison.
A teaching cardiologist who doesn’t read the NEJM, who pays no attention to the activities of the AHA, who is ignorant of current topics re clinical trials in his professional knowledge area, sounds like a member of the “them that can’t, teach” group. Or maybe the guy’s father is Steve Nissen.
Positive cash flow from operations is what matters. Until we see the liability side of the balance sheet we have no idea what cash flow for the quarter was from financing activities, including accounts payable.
In fact...I bought some July $23s this morning for .89 - Let it run!
I was at Datek (sp) when it was taken over by TDA, where I’ve now been for a very long time. thinkorswim is great for options trading imo but for other trading and for way better charts, level ii and raw data i very much prefer Medved Trader, which costs about $180 per year. Medved Trader is the current generation of a previous product called QuoteTracker which TDA used to provide free to active traders. You can set Medved Trader up to take feed from Ameritrade and can trade through that platform. You can search for the MT website if interested.
North, I have read your posts with great interest for a very long time. IANAL but my observation over years of investing in companies that had patent challenges is that infringers have been offered repeated bites of the apple at the PTAB, where claim construction and prior art are determined by political appointees who pursue their mission with little regard for the common law origins of our system. I do not fear the PTO examiners but I regard the PTAB ALJ’s as political hacks. I trust that we can get an honest result from an article III court, and I also believe that at the PTAB money talks.
G, you are a very smart guy and an invaluable resource for business questions, but you are so far out of your depth here that you can’t even see where the current has taken you. You should withdraw from this debate because the doctors on this board, the prescribers, are the real world.
There is a very important catch to keep in mind if you’re just approaching Medicare age. Once you enroll in an advantage plan or a supplement plan (plans Identified by letters A-G) you can never upgrade. You can change advantage plans or supplement plans with the same or lower letter but you can never upgrade to a higher level (go from an advantage plan to a supplement plan or to a higher letter supplement plan). Fortunately for me, when I was about to enroll my brother-in-law who is six months older, gave me this info, so I chose a plan F from the get-go. Plan F pays Medicare deductible and all medical co-pays in exchange for a higher monthly premium. I pay about $230 a month right now at age 75. The premium goes up with age. If I am hospitalized, get cancer, have a stroke etc, I have no copays. Supplement plans don’t cover medication however except while hospitalized, so if you choose the Medicare supplement route you also need a part D prescription drug plan (PDP).
One huge caution: I read somewhere that plan F is going to be discontinued for new enrollees but grandfathered in for current enrollees. In any case I recommend enrolling in the highest level of coverage available to you because the monthly premiums will become insignificant compared to the cost or the risk of cost of major medical issues.
This is a Medicare part D drug plan, available to people on Medicare with or without a Medicare supplement plan. I don’t think it’s available if you have a Medicare advantage plan because advantage plans Include both medical and drug coverage. I have a Medicare supplement plan F and a part D prescription drug plan.
Start here: https://www.silverscript.com/
I don’t think Silverscript is a single plan but rather multiple planes depending on the regional CVS policy. As mentioned in a recent post I have Silverscript in Northern California and my copay before I reached the donut hole would have been 36% of the total price, around $325 for three months. Now that I have reached the donut hole my copay is 25% of the total cost, About $238 for three months.